It is well known that a phenomenon called hyperprogressive disease (HPD) often occurs during immunotherapy with immune checkpoint inhibitors. In the present case, we experienced a case of HPD in a potential metastatic thyroid tumour during immunotherapy. HPD can be life-threatening depending on where it appears, so clinicians need to be careful.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506638 | PMC |
http://dx.doi.org/10.1002/rcr2.866 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!